# Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma

> **NCT06746480** · PHASE2 · RECRUITING · sponsor: **CNBG-Virogin Biotech (Shanghai) Ltd.** · enrollment: 33 (estimated)

## Conditions studied

- Advanced Intrahepatic Cholangiocarcinoma

## Interventions

- **DRUG:** Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

## Key facts

- **NCT ID:** NCT06746480
- **Lead sponsor:** CNBG-Virogin Biotech (Shanghai) Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-19
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06746480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06746480, "Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06746480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*